Lipodystrophy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
OMIM = | | OMIM = | | ||
MedlinePlus = | | MedlinePlus = | | ||
eMedicineSubj = | eMedicineSubj = | | ||
eMedicineTopic = | eMedicineTopic = | | ||
eMedicine_mult = | eMedicine_mult = | | ||
MeshID = D008060 | | MeshID = D008060 | | ||
}} | }} | ||
Revision as of 20:50, 17 February 2012
| Lipodystrophy | |
| ICD-10 | E88.1 |
|---|---|
| ICD-9 | 272.6 |
| DiseasesDB | 30066 |
| MeSH | D008060 |
|
WikiDoc Resources for Lipodystrophy |
|
Articles |
|---|
|
Most recent articles on Lipodystrophy Most cited articles on Lipodystrophy |
|
Media |
|
Powerpoint slides on Lipodystrophy |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lipodystrophy at Clinical Trials.gov Trial results on Lipodystrophy Clinical Trials on Lipodystrophy at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lipodystrophy NICE Guidance on Lipodystrophy
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lipodystrophy Discussion groups on Lipodystrophy Patient Handouts on Lipodystrophy Directions to Hospitals Treating Lipodystrophy Risk calculators and risk factors for Lipodystrophy
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lipodystrophy |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Lipodystrophy is a medical condition characterized by abnormal or degenerative conditions of the body's adipose tissue. ("Lipo" is Latin for "fat" and "dystrophy" is Latin for "abnormal or degenerative condition".) A more specific term, lipoatrophy is used when describing the loss of fat from one area (usually the face).
Insulin injections
A lipodystrophy can be a lump or small dent in the skin that forms when a person keeps performing injections in the same spot. These types of lipodystrophies are harmless. People who want to avoid them can do so by changing (rotating) the places where they perform injections. For people with diabetes, using purified insulins may also help.
One of the side-effects of lipodystrophy is the rejection of the injected medication, the slowing down of the absorption of the medication, or trauma that can cause bleeding that, in turn, will reject the medication. In either scenarios, the dosage of the medication, such as insulin for diabetics, becomes impossible to gauge correctly and the treatment of the disease for which the medication is administered is impaired thereby allowing the medical condition to worsen.
In some cases, rotation of the injection sites may not be enough to prevent lipodystrophy.
Antiretroviral drugs
Lipodystrophies can be a possible side effect of antiretroviral drugs. Other lipodystrophies manifest as lipid redistribution; with excess, or lack of, fat in various regions of the body. These include, but are not limited to, having sunken cheeks and/or "humps" on the back or back of the neck (also referred to as buffalo hump).[1]
Hereditary forms
Lipodystrophy can be caused by metabolic abnormalities due to genetic issues. These are often characterized by insulin resistance and are associated with Syndrome X.
References
- ↑ Physical and Biochemical Changes in HIV Disease Eric S. Daar, M.D. MedicineNet, Accessed 22 September 2007
See also
External links
Template:Lipid metabolism disorders
Template:SIB
de:Lipodystrophie nl:Lipodystrofie